>>Description of the research protocol "10053 : Mindact"

MINDACT (Microarray In node-Negative and 1 to 3 Positive Lymph node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemot
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Cancer du sein Adjuvant
Brugmann identifier : 10053 : Mindact
EudraCT identifier : 2005-002625-31
ClinicalTrials.gov identifier : NCT00433589


Involved department : Hemato-oncology
Principal investigator : Efira
Sponsor : EORTC
Contact : Clinical Research Unit

>This protocol was approved by the Bordet ethics committee.